The cardiometabolic diseases market is expected to reach US$ 121,804.49 million by 2028 from US$ 93,494.41 million in 2021; it is estimated to grow at a CAGR of 3.9% during 2021-2028. The report highlights trends prevailing in the market and factors driving its growth. The market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, the underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.
The prevention, control, and management of CMDs and their risk factors create substantial public health challenges requiring advanced approaches to be integrated in public health programs. Advancements in computers, electronics, telecommunication, and medicines have resulted in rapid development of health-related technology. For instance, the genomic prevention approach can identify people at risk of developing the disease, allowing early intervention for high-risk individuals to make lifestyle changes. In March 2021, NHS started trials for genomic testing to predict the risk of heart disease. With NHS, the UK biotech firm and Oxford University spin-off, Genomics plc is working on a pilot study that will use genetic information to predict the risk level of heart diseases. An integrated risk tool (IRT), created by Genomics plc, will be used to estimate each patient's risk of developing a CVD within the next 10 years. The company has claimed that if the IRT is applied to everybody aged between 40 and 60 in the UK, it could identify more than 650,000 people at high risk of CVDs, missed by current screening. Apart from this, recent advances on the Internet of Things (IoT), cloud computing, and artificial intelligence (AI) have significantly improved the conventional healthcare system. In August 2021, South Ural State University (SUSU) scientists have developed a model for more effective diagnosis of CVDs and diabetes, using AI and IoT.
Moreover, the integration of AI is further offering lucrative opportunities for the growth of the worldwide cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC's Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.
The cardiometabolic diseases market, by type, is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period. Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others. The ACE inhibitors segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR in the market during the forecast period. The cardiometabolic diseases market, based on dosage, is bifurcated into tablet and injection. The tablet segment held a larger share of the market in 2021 and is anticipated to register a higher CAGR in the market during the forecast period. Based on route of administration, the market is bifurcated into oral and intravenous. In 2021, the oral segment held a larger market share and is expected to register a higher CAGR in the market during the forecast period. Based on end users, the market is segmented into clinic, hospital, and homecare setting. In 2021, the hospital segment held the largest share of the market and is anticipated to register the highest CAGR in the market during the forecast period. Based on distribution channel, the cardiometabolic diseases market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest market share. The same segment is expected to register the highest CAGR in the market during the forecast period.
A few of the major primary and secondary sources referred to while preparing the report on the cardiometabolic diseases market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), International Diabetes Federation (IDF), and the National Center for Biotechnology Information (NCBI).Reasons to Buy
The prevention, control, and management of CMDs and their risk factors create substantial public health challenges requiring advanced approaches to be integrated in public health programs. Advancements in computers, electronics, telecommunication, and medicines have resulted in rapid development of health-related technology. For instance, the genomic prevention approach can identify people at risk of developing the disease, allowing early intervention for high-risk individuals to make lifestyle changes. In March 2021, NHS started trials for genomic testing to predict the risk of heart disease. With NHS, the UK biotech firm and Oxford University spin-off, Genomics plc is working on a pilot study that will use genetic information to predict the risk level of heart diseases. An integrated risk tool (IRT), created by Genomics plc, will be used to estimate each patient's risk of developing a CVD within the next 10 years. The company has claimed that if the IRT is applied to everybody aged between 40 and 60 in the UK, it could identify more than 650,000 people at high risk of CVDs, missed by current screening. Apart from this, recent advances on the Internet of Things (IoT), cloud computing, and artificial intelligence (AI) have significantly improved the conventional healthcare system. In August 2021, South Ural State University (SUSU) scientists have developed a model for more effective diagnosis of CVDs and diabetes, using AI and IoT.
Moreover, the integration of AI is further offering lucrative opportunities for the growth of the worldwide cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC's Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.
The cardiometabolic diseases market, by type, is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period. Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others. The ACE inhibitors segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR in the market during the forecast period. The cardiometabolic diseases market, based on dosage, is bifurcated into tablet and injection. The tablet segment held a larger share of the market in 2021 and is anticipated to register a higher CAGR in the market during the forecast period. Based on route of administration, the market is bifurcated into oral and intravenous. In 2021, the oral segment held a larger market share and is expected to register a higher CAGR in the market during the forecast period. Based on end users, the market is segmented into clinic, hospital, and homecare setting. In 2021, the hospital segment held the largest share of the market and is anticipated to register the highest CAGR in the market during the forecast period. Based on distribution channel, the cardiometabolic diseases market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest market share. The same segment is expected to register the highest CAGR in the market during the forecast period.
A few of the major primary and secondary sources referred to while preparing the report on the cardiometabolic diseases market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), International Diabetes Federation (IDF), and the National Center for Biotechnology Information (NCBI).Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 The Publisher's Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Cardiometabolic Diseases Market - By Type
1.3.2 Global Cardiometabolic Diseases Market - By Treatment
1.3.3 Global Cardiometabolic Diseases Market - By Dosage
1.3.4 Global Cardiometabolic Diseases Market - By Route of Administration
1.3.5 Global Cardiometabolic Diseases Market - By End Users
1.3.6 Global Cardiometabolic Diseases Market - By Distribution Channel
1.3.7 Global Cardiometabolic Diseases Market - By Geography
2. Global Cardiometabolic Diseases Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Cardiometabolic Diseases Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe- PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East and Africa - PEST Analysis
4.2.5 South and Central America (SCAM) - PEST Analysis
4.3 Experts Opinion
5. Cardiometabolic Diseases Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in CMDs Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Cardiometabolic Diseases Market - Global Analysis
6.1 Global Cardiometabolic Diseases Market Revenue Forecast and Analysis
6.2 Global Cardiometabolic Diseases Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Cardiometabolic Diseases Market Analysis- by Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2021 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Cardiometabolic Diseases Market Analysis - by Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2021 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Cardiometabolic Diseases Market Analysis- by Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2021 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Cardiometabolic Diseases Market Analysis- by Route of Administration
10.1 Overview
10.2 Global Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Cardiometabolic Diseases Market Analysis- by End Users
11.1 Overview
11.2 Global Cardiometabolic Diseases Market Share by End Users 2021 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Cardiometabolic Diseases Market Analysis- by Distribution Channel
12.1 Overview
12.2 Global Cardiometabolic Diseases Market Share by Distribution Channel 2021 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Global Cardiometabolic Diseases Market Geographic Analysis
13.1 North America: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 North America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.3 North America Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.1.4 North America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.1.5 North America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.1.6 North America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.1.7 North America Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million)
13.1.8 North America Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)
13.1.9 North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 US: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 US: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.9.1.2 US Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.1.9.1.3 US: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.1.9.1.4 US: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.1.9.1.5 US: Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
13.1.9.1.6 US: Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million)
13.1.9.1.7 US: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.1.9.2 Canada: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.9.2.1 Canada: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.9.2.2 Canada: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.1.9.2.3 Canada: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.1.9.2.4 Canada: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.1.9.2.5 Canada: Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
13.1.9.2.6 Canada: Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million)
13.1.9.2.7 Canada: Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)
13.1.9.3 Mexico: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.9.3.1 Mexico: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.9.3.2 Mexico: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.1.9.3.3 Mexico: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.1.9.3.4 Mexico: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.1.9.3.5 Mexico: Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
13.1.9.3.6 Mexico: Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million)
13.1.9.3.7 Mexico: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.2 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028
13.2.1 Overview
13.2.2 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.3 Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.4 Europe: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.5 Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.6 Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.7 Europe: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.2.8 Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.2.9 Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
13.2.9.1 Germany Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.9.1.1 Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.10 Germany: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.11 Germany: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.12 Germany: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.13 Germany: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.14 Germany: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.2.15 Germany: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.2.15.1 UK Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.15.1.1 UK; Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.16 UK: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.17 UK: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.18 UK: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.19 UK: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.20 UK: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.2.21 UK: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.2.21.1 France Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.21.1.1 France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.22 France: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.23 France: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.24 France: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.25 France: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.26 France: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.2.27 France: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.2.27.1 Italy Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.27.1.1 Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.28 Italy: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.29 Italy: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.30 Italy: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.31 Italy: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.32 Italy: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.2.33 Italy: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.2.33.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.33.1.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.34 Spain: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.35 Spain: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.36 Spain: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.37 Spain: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.38 Spain: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.2.39 Spain: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.2.39.1 Rest of Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.39.1.1 Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.2.40 Rest of Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.2.41 Rest of Europe: Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
13.2.42 Rest of Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.2.43 Rest of Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.2.44 Rest of Europe: Cardiometabolic Diseases Market, by End User Revenue and Forecast to 2028 (USD Million)
13.2.45 Rest of Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.3 Asia Pacific: Cardiometabolic Diseases Market
13.3.1 Overview
13.3.2 Asia Pacific: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.3 Asia Pacific: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.4 Asia Pacific: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.5 Asia Pacific: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.6 Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.7 Asia Pacific: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.8 Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.3.9 Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.3.9.1 China: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.9.1.1 China: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.10 China: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.11 China: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.12 China: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.13 China: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.14 China: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.15 China: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.3.15.1 Japan: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.15.1.1 Japan: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.16 Japan: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.17 Japan: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.18 Japan: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.19 Japan: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.20 Japan: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.3.21.1 India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million)
13.3.21.1.1 India: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.22 India: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.23 India: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.24 India: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.25 India: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.26 India: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.27 India: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.3.27.1 South Korea: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.27.1.1 South Korea: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.28 South Korea: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.29 South Korea: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.30 South Korea: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.32 South Korea: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.3.33.1 Australia: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.33.1.1 Australia: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.34 Australia: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.35 Australia: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.36 Australia: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.37 Australia: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.38 Australia: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.3.39.1 Rest of Asia Pacific: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.39.1.1 Rest of Asia Pacific: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.3.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.3.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.3.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.3.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.3.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.3.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.4 Middle East and Africa: Cardiometabolic Diseases Market
13.4.1 Overview
13.4.2 Middle East & Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.3 Middle East & Africa: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.4.4 Middle East & Africa: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.4.5 Middle East & Africa: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.4.6 Middle East & Africa: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.4.7 Middle East & Africa: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.4.8 Middle East & Africa: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.4.9 Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.4.9.1 Saudi Arabia: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.9.1.1 Saudi Arabia: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.10 Saudi Arabia: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.4.11 Saudi Arabia: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.4.12 Saudi Arabia: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.4.13 Saudi Arabia: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.4.14 Saudi Arabia: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.4.15 Saudi Arabia: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.4.15.1 UAE: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.15.1.1 UAE: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.15.1.2 UAE: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.16 UAE: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.4.17 UAE: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.4.18 UAE: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.4.19 UAE: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.4.20 UAE: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.4.21 UAE: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.4.21.1 South Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.21.1.1 South Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.22 South Africa: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.4.23 South Africa: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.4.24 South Africa: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.4.25 South Africa: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.4.26 South Africa: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.4.27 South Africa: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.4.27.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.27.1.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.4.28 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.4.29 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.4.30 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.4.31 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.4.32 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.4.33 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.5 South and Central America: Cardiometabolic Diseases Market
13.5.1 Overview
13.5.2 South and Central America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.3 South and Central America: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.5.4 South and Central America: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.5.5 South and Central America: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.5.6 South and Central America: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.5.7 South and Central America: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.5.8 South and Central America: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.5.9 South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.5.9.1 Brazil: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.9.1.1 Brazil: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.10 Brazil: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.5.11 Brazil: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.5.12 Brazil: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.5.13 Brazil: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.5.14 Brazil: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.5.15 Brazil: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.5.15.1 Argentina: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.15.1.1 Argentina: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.16 Argentina: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.5.17 Argentina: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.5.18 Argentina: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.5.19 Argentina: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.5.20 Argentina: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.5.21 Argentina: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
13.5.21.1 Rest of South and Central America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.21.1.1 Rest of South and Central America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.5.22 Rest of South and Central America: Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
13.5.23 Rest of South and Central America: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
13.5.24 Rest of South and Central America: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
13.5.25 Rest of South and Central America: Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
13.5.26 Rest of South and Central America: Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
13.5.27 Rest of South and Central America: Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
14. Impact Of COVID-19 Pandemic on Cardiometabolic Diseases Market
14.1 North America: Impact Assessment of COVID-19 Pandemic
14.2 Europe: Impact Assessment of COVID-19 Pandemic
14.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
14.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
14.5 South and Central America: Impact Assessment of COVID-19 Pandemic
15. Cardiometabolic Diseases Market-Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Arrowhead Pharmaceuticals, Inc
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novartis AG
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Boehringer Ingelheim International GmbH
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 Novo Nordisk A/S
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 AstraZeneca
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Alnylam Pharmaceuticals, Inc.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
16.9 Cardax, Inc.
16.9.1 Key Facts
16.9.2 Business Description
16.9.3 Products and Services
16.9.4 Financial Overview
16.9.5 SWOT Analysis
16.9.6 Key Developments
16.10 Kowa Company, Ltd.
16.10.1 Key Facts
16.10.2 Business Description
16.10.3 Products and Services
16.10.4 Financial Overview
16.10.5 SWOT Analysis
16.10.6 Key Developments
17. Appendix
17.1 About The Publisher
17.2 Glossary of Terms
List of Tables
Table 1. North America Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 2. North America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 3. North America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 4. North America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 5. North America Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 6. North America Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)
Table 7. US Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 8. US Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 9. US Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 10. US Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
Table 11. US Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 12. US Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 13. Canada: Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 14. Canada: Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 15. Canada: Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 16. Canada: Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
Table 17. Canada: Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 18. Canada: Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)
Table 19. Mexico Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 20. Mexico Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 21. Mexico Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 22. Mexico Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
Table 23. Mexico Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million)
Table 24. Mexico Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 25. Europe Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 26. Europe Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 27. Europe Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 28. Europe Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 29. Europe Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 30. Europe Cardiometabolic Diseases Market, by Distribution Channel, - Revenue and Forecast to 2028 (USD Million)
Table 31. Germany Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 32. Germany Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 33. Germany Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 34. Germany Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 35. Germany Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 36. Germany Cardiometabolic Diseases Market, by Distribution Channel, - Revenue and Forecast to 2028 (USD Million)
Table 37. UK Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 38. UK Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 39. UK Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 40. UK Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 41. UK Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 42. UK Cardiometabolic Diseases Market, by Distribution Channel, - Revenue and Forecast to 2028 (USD Million)
Table 43. France Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 44. France Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 45. France Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 46. France Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 47. France Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 48. France Cardiometabolic Diseases Market, by Distribution Channel, - Revenue and Forecast to 2028 (USD Million)
Table 49. Italy Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 50. Italy Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 51. Italy Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 52. Italy Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 53. Italy Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 54. Italy Cardiometabolic Diseases Market, by Distribution Channel, - Revenue and Forecast to 2028 (USD Million)
Table 55. Spain Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 56. Spain Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 57. Spain Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 58. Spain Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 59. Spain Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 60. Spain Cardiometabolic Diseases Market, by Distribution Channel, - Revenue and Forecast to 2028 (USD Million)
Table 61. Rest of Europe Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 62. Rest of Europe Cardiometabolic Diseases Market, by Treatment- Revenue and Forecast to 2028 (USD Million)
Table 63. Rest of Europe Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 64. Rest of Europe Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million
Table 65. Rest of Europe Cardiometabolic Diseases Market, by End User - Revenue and Forecast to 2028 (USD Million
Table 66. Rest of Europe Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 67. Asia Pacific Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 68. Asia Pacific Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 69. Asia Pacific Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 70. Asia Pacific Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 71. Asia Pacific Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 72. Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 73. China Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 74. China Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 75. China Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 76. China Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 77. China Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 78. China Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 79. Japan Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 80. Japan Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 81. Japan Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 82. Japan Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 83. Japan Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 84. Japan Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 85. India Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 86. India Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 87. India Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 88. India Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 89. India Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 90. India Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 91. South Korea Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 92. South Korea Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 93. South Korea Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 94. South Korea Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 95. South Korea Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 96. South Korea Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 97. Australia Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 98. Australia Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 99. Australia Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 100. Australia Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 101. Australia Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 102. Australia Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 103. Rest of Asia Pacific Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 104. Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 105. Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 106. Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 107. Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 108. Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 109. Middle East & Africa Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 110. Middle East & Africa Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 111. Middle East & Africa Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 112. Middle East & Africa Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 113. Middle East & Africa Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 114. Middle East & Africa Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 115. Saudi Arabia Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 116. Saudi Arabia Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 117. Saudi Arabia Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 118. Saudi Arabia Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 119. Saudi Arabia Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 120. Saudi Arabia Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 121. UAE Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 122. UAE Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 123. UAE Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 124. UAE Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 125. UAE Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 126. UAE Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 127. South Africa Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 128. South Africa Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 129. South Africa Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 130. South Africa Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 131. South Africa Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 132. South Africa Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 133. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 134. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 135. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 136. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 137. Rest of Middle East and Africa Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 138. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 139. South and Central America Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 140. South and Central America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 141. South and Central America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 142. South and Central America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 143. South and Central America Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 144. South and Central America Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 145. Brazil Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 146. Brazil Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 147. Brazil Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 148. Brazil Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 149. Brazil Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 150. Brazil Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 151. Argentina Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 152. Argentina Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 153. Argentina Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 154. Argentina Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 155. Argentina Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 156. Argentina Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 157. Rest of South and Central America Cardiometabolic Diseases Market, by Type - Revenue and Forecast to 2028 (USD Million)
Table 158. Rest of South and Central America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 159. Rest of South and Central America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 160. Rest of South and Central America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 161. Rest of South and Central America Cardiometabolic Diseases Market, by End Users - Revenue and Forecast to 2028 (USD Million)
Table 162. Rest of South and Central America Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 163. Organic Developments in the Cardiometabolic Diseases Market
Table 164. Inorganic Developments in the Cardiometabolic Diseases Market
Table 165. Glossary of Terms, Cardiometabolic Diseases MarketList of Figures
Figure 1. Cardiometabolic Diseases Market Segmentation
Figure 2. Cardiometabolic Diseases Market Segmentation, By Region
Figure 3. Global Cardiometabolic Diseases Market Overview
Figure 4. Cardiovascular disease Held the Largest Share of the Product Segment in Cardiometabolic Diseases Market
Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
Figure 6. Cardiometabolic Diseases Market, by Geography (US$ Million)
Figure 7. Global Cardiometabolic Diseases Market - Leading Country Markets (US$ Million)
Figure 8. Global Cardiometabolic Diseases Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe and PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East and Africa PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 15. Global Cardiometabolic Diseases Market - Revenue Forecast and Analysis - 2020- 2028
Figure 16. Global Cardiometabolic Diseases Market - By Geography Forecast and Analysis - 2021- 2028
Figure 17. Market Positioning of Key Players in Global Cardiometabolic Diseases Market
Figure 18. Cardiometabolic Diseases Market Revenue Share, by Type (2021 and 2028)
Figure 19. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 20. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 23. Cardiometabolic Diseases Market Revenue Share, by Treatment (2021 and 2028)
Figure 24. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 26. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Cardiometabolic Diseases Market Revenue Share, by Dosage (2021 and 2028)
Figure 29. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 30. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Global Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 32. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 34. Global Cardiometabolic Diseases Market Share by End Users 2021 & 2028 (%)
Figure 35. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 36. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 37. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 38. Global Cardiometabolic Diseases Market Share by Distribution Channel 2021 & 2028 (%)
Figure 39. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 40. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 41. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 42. North America: Cardiometabolic Diseases Market, by Key Country - Revenue (2021) (USD Million)
Figure 43. North America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 44. North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 45. US: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 46. Canada: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 47. Mexico: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 48. Europe: Cardiometabolic Diseases Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 49. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 50. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
Figure 51. Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 52. UK: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 53. France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 54. Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 55. Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 56. Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 57. Asia Pacific: Cardiometabolic Diseases Market, by Key Country - Revenue (2021) (USD Million)
Figure 58. Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 59. Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 60. China Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 61. Japan: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 62. India: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 63. South Korea: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 64. Australia: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 65. Rest of Asia Pacific: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 66. Middle East and Africa: Cardiometabolic Diseases Market, by Key Country - Revenue (2021) (USD Million)
Figure 67. Middle East & Africa Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Million)
Figure 68. Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 69. Saudi Arabia: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. UAE: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. South Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
Figure 72. Rest of Middle East and Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. South and Central America: Cardiometabolic Diseases Market, by Key Country - Revenue (2021) (USD Million)
Figure 74. South and Central America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 75. South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 76. Brazil: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 77. Argentina: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 78. Rest of South and Central America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
Figure 79. Impact of COVID-19 Pandemic in North American Country Markets
Figure 80. Impact of COVID-19 Pandemic in European Country Markets
Figure 81. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 82. Impact Of COVID-19 Pandemic in Middle East and Africa Country Markets
Figure 83. Impact Of COVID-19 Pandemic in South and Central America Africa Country Markets
Figure 84. Growth Strategies in the Cardiometabolic Diseases Market (%)
Companies Mentioned
- Eli Lilly and Company
- Bayer AG
- Arrowhead Pharmaceuticals, Inc
- Novartis AG
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Cardax, Inc
- Kowa Company, Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 293 |
| Published | October 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 93494.41 Million |
| Forecasted Market Value ( USD | $ 121804.49 Million |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
